IONIS PHARMACEUTICALS INC
olezarsen
severe hypertriglyceridemia
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on olezarsen for severe hypertriglyceridemia is expected Date TBD.
Primary source
· SEC 8-K
verified 12h ago
“TRYNGOLZA outperformed expectations as the first U.S. Food and Drug Administration (FDA)-approved treatment for familial chylomicronemia syndrome (FCS), generating $105* million in preliminary U.S. net product sales in 2025”